Sacituzumab govitecan, the first-in-class antibody-drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2), has demonstrated promising efficacy and safety in several clinical trials for cervical cancer. The gene discussed is TACSTD2; the disease is cervical carcinoma.